The role of microRNAs in heart failure

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1863, Issue 8, 2017, Pages 2019-2030

  Wang, Hongjiang ^a   Cai, Jun ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

Angiogenesis; Apoptosis; Fibrosis; Heart failure; Hypertrophy; MicroRNA

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 101A; MICRORNA 126; MICRORNA 132; MICRORNA 133; MICRORNA 138; MICRORNA 15; MICRORNA 155; MICRORNA 17 92; MICRORNA 181C; MICRORNA 185; MICRORNA 199B; MICRORNA 19A 3P; MICRORNA 19B 3P; MICRORNA 208; MICRORNA 21; MICRORNA 210; MICRORNA 212; MICRORNA 214; MICRORNA 22; MICRORNA 23; MICRORNA 24; MICRORNA 26A; MICRORNA 28; MICRORNA 29; MICRORNA 30; MICRORNA 34; MICRORNA 378; MICRORNA 499; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR FUNCTION; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; HEART FAILURE; HUMANS; MICRORNAS; SIGNAL TRANSDUCTION;

EID: 85010755083     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.11.034     Document Type: Review

References (158)

1. Trupp, R.J., Abraham, W.T., American College of Cardiology/American Heart Association 2009 clinical guidelines for the diagnosis and management of heart failure in adults: update and clinical implications. Pol. Arch. Med. Wewn. 119:7–8 (2009), 436–438.
2. Yancy, C.W., et al., 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol., 2016.
3. Hill, J.A., Olson, E.N., Cardiac plasticity. N. Engl. J. Med. 358:13 (2008), 1370–1380.
4. Berezin, A., Epigenetics in heart failure phenotypes. BBA Clin. 6 (2016), 31–37.
5. Stewart, S., et al. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail. 3:3 (2001), 315–322.
6. Alla, F., Zannad, F., Filippatos, G., Epidemiology of acute heart failure syndromes. Heart Fail. Rev. 12:2 (2007), 91–95.
7. Kehat, I., Molkentin, J.D., Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122:25 (2010), 2727–2735.
8. Johnson, F.L., Pathophysiology and etiology of heart failure. Cardiol. Clin. 32:1 (2014), 9–19 (vii).
9. Filipowicz, W., Bhattacharyya, S.N., Sonenberg, N., Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 9:2 (2008), 102–114.
10. Consortium, E.P., An integrated encyclopedia of DNA elements in the human genome. Nature 489:7414 (2012), 57–74.
11. Ecker, J.R., et al. Genomics: ENCODE explained. Nature 489:7414 (2012), 52–55.
12. Djebali, S., et al. Landscape of transcription in human cells. Nature 489:7414 (2012), 101–108.
13. Gerstein, M.B., et al. Architecture of the human regulatory network derived from ENCODE data. Nature 489:7414 (2012), 91–100.
14. Neph, S., et al. An expansive human regulatory lexicon encoded in transcription factor footprints. Nature 489:7414 (2012), 83–90.
15. Ha, M., Kim, V.N., Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15:8 (2014), 509–524.
16. Vasudevan, S., Tong, Y., Steitz, J.A., Switching from repression to activation: microRNAs can up-regulate translation. Science 318:5858 (2007), 1931–1934.
17. Mitchell, P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105:30 (2008), 10513–10518.
18. Chen, X., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:10 (2008), 997–1006.
19. Lawrie, C.H., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141:5 (2008), 672–675.
20. Dawson, K., et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 127:14 (2013), 1466–1475 (1475e1-28).
21. Eitel, I., et al. Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. Am. Heart J. 164:5 (2012), 706–714.
22. Oka, T., et al. Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ. Res. 114:3 (2014), 565–571.
23. Wang, S., Olson, E.N., AngiomiRs–key regulators of angiogenesis. Curr. Opin. Genet. Dev. 19:3 (2009), 205–211.
24. Doebele, C., et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 115:23 (2010), 4944–4950.
25. Ohyagi-Hara, C., et al. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin alpha5 expression. Am. J. Pathol. 182:5 (2013), 1876–1889.
26. Bonauer, A., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324:5935 (2009), 1710–1713.
27. Hinkel, R., et al. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation 128:10 (2013), 1066–1075.
28. Wang, S., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15:2 (2008), 261–271.
29. Chistiakov, D.A., Orekhov, A.N., Bobryshev, Y.V., The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. J. Mol. Cell. Cardiol. 97 (2016), 47–55.
30. Jakob, P., et al. Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: role for impaired in vivo neovascularization and cardiac repair capacity. Circulation 126:25 (2012), 2962–2975.
31. Fish, J.E., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 15:2 (2008), 272–284.
32. Taniguchi, K., et al. Spreds are essential for embryonic lymphangiogenesis by regulating vascular endothelial growth factor receptor 3 signaling. Mol. Cell. Biol. 27:12 (2007), 4541–4550.
33. Silva ND, D.A. Jr., et al. Swimming training in rats increases cardiac MicroRNA-126 expression and angiogenesis. Med. Sci. Sports Exerc. 44:8 (2012), 1453–1462.
34. Fiedler, J., et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124:6 (2011), 720–730.
35. Meloni, M., et al. Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol. Ther. 21:7 (2013), 1390–1402.
36. Duan, Q., et al. MicroRNA-214 is upregulated in heart failure patients and suppresses XBP1-mediated endothelial cells angiogenesis. J. Cell. Physiol. 230:8 (2015), 1964–1973.
37. Boon, R.A., et al. MicroRNA-34a regulates cardiac ageing and function. Nature 495:7439 (2013), 107–110.
38. Ito, T., Yagi, S., Yamakuchi, M., MicroRNA-34a regulation of endothelial senescence. Biochem. Biophys. Res. Commun. 398:4 (2010), 735–740.
39. Zhao, T., Li, J., Chen, A.F., MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am. J. Physiol. Endocrinol. Metab. 299:1 (2010), E110–E116.
40. Xu, Q., et al. Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease. J. Am. Coll. Cardiol. 59:23 (2012), 2107–2117.
41. Bernardo, B.C., et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl. Acad. Sci. U. S. A. 109:43 (2012), 17615–17620.
42. Hu, S., et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 122:11 Suppl (2010), S124–S131.
43. Endo, K., et al. MicroRNA 210 as a biomarker for congestive heart failure. Biol. Pharm. Bull. 36:1 (2013), 48–54.
44. Fasanaro, P., et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J. Biol. Chem. 283:23 (2008), 15878–15883.
45. Zhao, Y., et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129:2 (2007), 303–317.
46. Rao, P.K., et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ. Res. 105:6 (2009), 585–594.
47. Care, A., et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13:5 (2007), 613–618.
48. Zhang, R., et al. Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. Int. J. Cardiol. 166:1 (2013), 259–260.
49. Gidlof, O., et al. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc. Disord., 13, 2013, 12.
50. Sayed, D., et al. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res. 100:3 (2007), 416–424.
51. Ikeda, S., et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol. Cell. Biol. 29:8 (2009), 2193–2204.
52. Elia, L., et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 120:23 (2009), 2377–2385.
53. Hua, Y., Zhang, Y., Ren, J., IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: role of microRNA-1 and microRNA-133a. J. Cell. Mol. Med. 16:1 (2012), 83–95.
54. Li, Q., et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J. Cell Sci. 123:Pt 14 (2010), 2444–2452.
55. Karakikes, I., et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J. Am. Heart Assoc., 2(2), 2013, e000078.
56. Varrone, F., et al. The circulating level of FABP3 is an indirect biomarker of microRNA-1. J. Am. Coll. Cardiol. 61:1 (2013), 88–95.
57. He, M., et al. GTPase activating protein (Sh3 domain) binding protein 1 regulates the processing of microRNA-1 during cardiac hypertrophy. PLoS One, 10(12), 2015, e0145112.
58. Villar, A.V., et al. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int. J. Cardiol. 167:6 (2013), 2875–2881.
59. Danowski, N., et al. Decreased expression of miR-133a but not of miR-1 is associated with signs of heart failure in patients undergoing coronary bypass surgery. Cardiology 125:2 (2013), 125–130.
60. Dong, D.L., et al. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension 55:4 (2010), 946–952.
61. Diniz, G.P., et al. Cardiac microRNA-133 is down-regulated in thyroid hormone-mediated cardiac hypertrophy partially via type 1 angiotensin II receptor. Basic Res. Cardiol., 110(5), 2015, 49.
62. Feng, B., et al. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab. Res. Rev. 26:1 (2010), 40–49.
63. Chen, S., et al. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J. Cell. Mol. Med. 18:3 (2014), 415–421.
64. Chavali, V., Tyagi, S.C., Mishra, P.K., MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes. Biochem. Biophys. Res. Commun. 425:3 (2012), 668–672.
65. Zhang, X., et al. Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. Am. J. Physiol. Heart Circ. Physiol. 280:4 (2001), H1782–H1792.
66. Chen, J.F., et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38:2 (2006), 228–233.
67. Sprenkle, A.B., Murray, S.F., Glembotski, C.C., Involvement of multiple cis elements in basal- and alpha-adrenergic agonist-inducible atrial natriuretic factor transcription. Roles for serum response elements and an SP-1-like element. Circ. Res. 77:6 (1995), 1060–1069.
68. Nelson, T.J., et al. SRF-dependent gene expression in isolated cardiomyocytes: regulation of genes involved in cardiac hypertrophy. J. Mol. Cell. Cardiol. 39:3 (2005), 479–489.
69. Ganesan, J., et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127:21 (2013), 2097–2106.
70. Nagalingam, R.S., et al. A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J. Biol. Chem. 288:16 (2013), 11216–11232.
71. Kim, J.O., et al. miR-185 plays an anti-hypertrophic role in the heart via multiple targets in the calcium-signaling pathways. PLoS One, 10(3), 2015, e0122509.
72. Seok, H.Y., et al. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy. Circ. Res. 114:10 (2014), 1585–1595.
73. Heymans, S., et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 128:13 (2013), 1420–1432.
74. Yang, Y., et al. miR-155 functions downstream of angiotensin II receptor subtype 1 and calcineurin to regulate cardiac hypertrophy. Exp. Ther. Med. 12:3 (2016), 1556–1562.
75. Huang, X., et al. High expression of microRNA-208 is associated with cardiac hypertrophy via the negative regulation of the sex-determining region Y-box 6 protein. Exp. Ther. Med. 10:3 (2015), 921–926.
76. Wang, H.R., et al. Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133. ACS Chem. Biol. 6:8 (2011), 845–856.
77. Callis, T.E., et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119:9 (2009), 2772–2786.
78. Montgomery, R.L., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124:14 (2011), 1537–1547.
79. Ucar, A., et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun., 3, 2012, 1078.
80. Mayer, S.C., et al. Adrenergic repression of the epigenetic reader MeCP2 facilitates cardiac adaptation in chronic heart failure. Circ. Res. 117:7 (2015), 622–633.
81. da Costa Martins, P.A., et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat. Cell Biol. 12:12 (2010), 1220–1227.
82. Xu, X.D., et al. Attenuation of microRNA-22 derepressed PTEN to effectively protect rat cardiomyocytes from hypertrophy. J. Cell. Physiol. 227:4 (2012), 1391–1398.
83. Huang, Z.P., et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ. Res. 112:9 (2013), 1234–1243.
84. Lin, Z., et al. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 106:29 (2009), 12103–12108.
85. Wang, K., et al. Cardiac hypertrophy is positively regulated by microRNA miR-23a. J. Biol. Chem. 287:1 (2012), 589–599.
86. Baum, J., Duffy, H.S., Fibroblasts and myofibroblasts: what are we talking about?. J. Cardiovasc. Pharmacol. 57:4 (2011), 376–379.
87. Abonnenc, M., et al. Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ. Res. 113:10 (2013), 1138–1147.
88. Manzoni, G.M., Castelnuovo, G., Proietti, R., Assessment of psychosocial risk factors is missing in the 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. J. Am. Coll. Cardiol. 57:14 (2011), 1569–1570 (author reply 1571).
89. van Rooij, E., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A. 105:35 (2008), 13027–13032.
90. Romero, R., et al. Transcriptome interrogation of human myometrium identifies differentially expressed sense-antisense pairs of protein-coding and long non-coding RNA genes in spontaneous labor at term. J. Matern. Fetal Neonatal Med. 27:14 (2014), 1397–1408.
91. Zhang, Y., et al. miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling. Mol. Ther. 22:5 (2014), 974–985.
92. Zhou, L., et al. Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts. PLoS One, 7(3), 2012, e33766.
93. Zhu, J.N., et al. Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat. PLoS One, 8(9), 2013, e75557.
94. Liu, N., et al. MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 22:23 (2008), 3242–3254.
95. Matkovich, S.J., et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ. Res. 106:1 (2010), 166–175.
96. Shan, H., et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc. Res. 83:3 (2009), 465–472.
97. Castoldi, G., et al. MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J. Cell. Physiol. 227:2 (2012), 850–856.
98. Angelini, A., et al. Regulation of connective tissue growth factor and cardiac fibrosis by an SRF/microRNA-133a axis. PLoS One, 10(10), 2015, e0139858.
99. Duisters, R.F., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 104:2 (2009), 170–178 (6p following 178).
100. Matkovich, S.J., et al. RISC RNA sequencing for context-specific identification of in vivo microRNA targets. Circ. Res. 108:1 (2011), 18–26.
101. Wei, C., et al. NF-kappaB mediated miR-26a regulation in cardiac fibrosis. J. Cell. Physiol. 228:7 (2013), 1433–1442.
102. Qi, X.Y., et al. Fibroblast inward-rectifier potassium current upregulation in profibrillatory atrial remodeling. Circ. Res. 116:5 (2015), 836–845.
103. Harada, M., et al. Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation 126:17 (2012), 2051–2064.
104. Zou, M., et al. Autophagy inhibition of hsa-miR-19a-3p/19b-3p by targeting TGF-beta R II during TGF-beta1-induced fibrogenesis in human cardiac fibroblasts. Sci. Rep., 6, 2016, 24747.
105. Wang, J., et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J. Cell. Mol. Med. 16:9 (2012), 2150–2160.
106. Xu, M., et al. Mir-24 regulates junctophilin-2 expression in cardiomyocytes. Circ. Res. 111:7 (2012), 837–841.
107. Pan, Z., et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 126:7 (2012), 840–850.
108. Zhao, X., et al. MicroRNA-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGFbetaRI on cardiac fibroblasts. Cell. Physiol. Biochem. 35:1 (2015), 213–226.
109. Thum, T., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:7224 (2008), 980–984.
110. Yang, K.C., et al. Combined deep microRNA and mRNA sequencing identifies protective transcriptomal signature of enhanced PI3Kalpha signaling in cardiac hypertrophy. J. Mol. Cell. Cardiol. 53:1 (2012), 101–112.
111. Liang, H., et al. A novel reciprocal loop between microRNA-21 and TGFbetaRIII is involved in cardiac fibrosis. Int. J. Biochem. Cell Biol. 44:12 (2012), 2152–2160.
112. Lorenzen, J.M., et al. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. Eur. Heart J. 36:32 (2015), 2184–2196.
113. Bronnum, H., et al. miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving Programmed Cell Death 4 and Sprouty-1. PLoS One, 8(2), 2013, e56280.
114. Cardin, S., et al. Role for microRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ. Arrhythm. Electrophysiol. 5:5 (2012), 1027–1035.
115. He, X., et al. Rapid atrial pacing induces myocardial fibrosis by down-regulating Smad7 via microRNA-21 in rabbit. Heart Vessels, 2016.
116. Patrick, D.M., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest. 120:11 (2010), 3912–3916.
117. van Rooij, E., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U. S. A. 103:48 (2006), 18255–18260.
118. Tijsen, A.J., et al. The microRNA-15 family inhibits the TGFbeta-pathway in the heart. Cardiovasc. Res. 104:1 (2014), 61–71.
119. Hullinger, T.G., et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 110:1 (2012), 71–81.
120. Porrello, E.R., et al. Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc. Natl. Acad. Sci. U. S. A. 110:1 (2013), 187–192.
121. Luo, X., et al. Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J. Biol. Chem. 283:29 (2008), 20045–20052.
122. Belevych, A.E., et al. MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One, 6(12), 2011, e28324.
123. Curcio, A., et al. MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts. PLoS One, 8(7), 2013, e70158.
124. Liu, M., et al. The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. Biomaterials 35:11 (2014), 3697–3707.
125. Terentyev, D., et al. miR-1 overexpression enhances Ca(2 +) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ. Res. 104:4 (2009), 514–521.
126. Schiattarella, G.G., Hill, J.A., Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation 131:16 (2015), 1435–1447.
127. Briasoulis, A., et al. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail. Rev. 21:2 (2016), 169–176.
128. Galluzzi, L., et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 22:1 (2015), 58–73.
129. Elmore, S., Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35:4 (2007), 495–516.
130. Xu, C., et al. beta-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression. J. Mol. Cell. Cardiol. 75 (2014), 111–121.
131. Volk, N., et al. MicroRNA-19b associates with Ago2 in the amygdala following chronic stress and regulates the adrenergic receptor beta 1. J. Neurosci. 34:45 (2014), 15070–15082.
132. He, B., et al. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J. Biomed. Sci., 18, 2011, 22.
133. Wei, C., et al. NF-kappaB mediated miR-21 regulation in cardiomyocytes apoptosis under oxidative stress. Free Radic. Res. 48:3 (2014), 282–291.
134. Cheng, Y., et al. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J. Mol. Cell. Cardiol. 47:1 (2009), 5–14.
135. Yang, Q., Yang, K., Li, A., MicroRNA-21 protects against ischemia-reperfusion and hypoxia-reperfusion-induced cardiocyte apoptosis via the phosphatase and tensin homolog/Akt-dependent mechanism. Mol. Med. Rep. 9:6 (2014), 2213–2220.
136. Roy, S., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 82:1 (2009), 21–29.
137. Viappiani, S., et al. Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem. Pharmacol. 77:5 (2009), 826–834.
138. Huang, Z., et al. MicroRNA-21 protects against cardiac hypoxia/reoxygenation injury by inhibiting excessive autophagy in H9c2 cells via the Akt/mTOR pathway. J. Cell. Mol. Med., 2016.
139. Huang, W., et al. Combination of microRNA-21 and microRNA-146a attenuates cardiac dysfunction and apoptosis during acute myocardial infarction in mice. Mol. Ther. Nucleic Acids, 5, 2016, e296.
140. Dong, S., et al. MicroRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int. J. Clin. Exp. Pathol. 7:2 (2014), 565–574.
141. Li, J., et al. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet., 6(1), 2010, e1000795.
142. Roca-Alonso, L., et al. Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in beta-adrenergic signaling and enhances apoptosis. Cell Death Dis., 6, 2015, e1754.
143. Xiong, H., et al. Up-regulation of miR-138 inhibits hypoxia-induced cardiomyocyte apoptosis via down-regulating lipocalin-2 expression. Exp. Biol. Med. (Maywood) 241:1 (2016), 25–30.
144. Brancho, D., et al. Role of MLK3 in the regulation of mitogen-activated protein kinase signaling cascades. Mol. Cell. Biol. 25:9 (2005), 3670–3681.
145. Gallo, K.A., Johnson, G.L., Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 3:9 (2002), 663–672.
146. He, S., et al. miR-138 protects cardiomyocytes from hypoxia-induced apoptosis via MLK3/JNK/c-jun pathway. Biochem. Biophys. Res. Commun. 441:4 (2013), 763–769.
147. Chua, S.K., et al. Mechanical stretch inhibits microRNA499 via p53 to regulate calcineurin-A expression in rat cardiomyocytes. PLoS One, 11(2), 2016, e0148683.
148. Wang, H., et al. MicroRNA-181c targets Bcl-2 and regulates mitochondrial morphology in myocardial cells. J. Cell. Mol. Med. 19:9 (2015), 2084–2097.
149. Zhu, R.Y., et al. MiR-28 inhibits cardiomyocyte survival through suppressing PDK1/Akt/mTOR signaling. In Vitro Cell. Dev. Biol. Anim., 2016.
150. Budas, G.R., Disatnik, M.H., Mochly-Rosen, D., Aldehyde dehydrogenase 2 in cardiac protection: a new therapeutic target?. Trends Cardiovasc. Med. 19:5 (2009), 158–164.
151. Chen, C.H., et al. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 321:5895 (2008), 1493–1495.
152. Ma, H., et al. Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde. Eur. Heart J. 32:8 (2011), 1025–1038.
153. Li, S.P., et al. miR-28 promotes cardiac ischemia by targeting mitochondrial aldehyde dehydrogenase 2 (ALDH2) in mus musculus cardiac myocytes. Eur. Rev. Med. Pharmacol. Sci. 19:5 (2015), 752–758.
154. Fukushima, Y., et al. Assessment of plasma miRNAs in congestive heart failure. Circ. J. 75:2 (2011), 336–340.
155. Tijsen, A.J., et al. MiR423-5p as a circulating biomarker for heart failure. Circ. Res. 106:6 (2010), 1035–1039.
156. Ellis, K.L., et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur. J. Heart Fail. 15:10 (2013), 1138–1147.
157. Hata, A., Functions of microRNAs in cardiovascular biology and disease. Annu. Rev. Physiol. 75 (2013), 69–93.
158. Suckau, L., et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119:9 (2009), 1241–1252.